质子泵抑制剂与胃黏膜保护剂治疗咽喉反流性疾病临床疗效及安全性对比的Meta分析

doi:10.6040/j.issn.1673-3770.0.2024.491

摘要/Abstract

摘要： 目的利用Meta分析的方法分析质子泵抑制剂(proton pump inhibitors, PPIs)与胃黏膜保护剂治疗咽喉反流性疾病(laryngopharygeal reflux disease, LPRD)的临床疗效和安全性。方法用计算机检索知网、万方、维普、CBM、PubMed、Embase、Cochrane library、Web of Science中英文数据库,搜集有关PPIs、胃黏膜保护剂与LPRD相关的研究,时间范围为建库起至2024年9月。由两名独立评价者筛选文献、提取资料,并用R4.3.1软件对符合质量标准的研究进行Meta分析。结果最终纳入了6项随机对照试验(randomized controlled trials, RCT),Meta分析结果显示PPIs治疗LPRD有效率优于使用胃黏膜保护剂［RR=1.19(95%CI:1.10~1.29, P<0.001)］;PPIs治疗LPRD不良反应发生率较使用胃黏膜保护剂差异无统计学意义［RR=0.51(95%CI:0.18~1.41,P=0.19)］;差异均有统计学意义。结论在LPRD疗程不超过4周的短期治疗中,PPIs较胃黏膜保护剂能显著提高临床疗效,但其不良反应的发生率与胃黏膜保护剂无明显差异。

关键词: 质子泵抑制剂, 胃黏膜保护剂, 咽喉反流性疾病, Meta分析

Abstract: Objective To analyse the clinical effectiveness and safety of proton pump inhibitors(PPIs)and gastric mucosal protectors in the treatment of laryngopharygeal reflux disease(LPRD)by Meta-analysis. Methods The CNKI, Wanfang, VIP, CBM, PubMed, Embase, Cochrane library, Web of Science databases on PPIs, gastric mucosal protectors and LPRD were retrieved up to September 2024. Two reviewers screened the literature, extracted data and performed meta-analysis of studies that met the quality criteria using R4.3.1 software. Results Six randomised controlled trials(RCT)were included, and the results of the meta-analysis showed that the response rate of LPRD with PPIs was better than that of gastric mucosal protectors ［RR=1.19(95%CI:1.10-1.29, P<0.000 1)］; the incidence of adverse reactions of PPI treatment in LPRD was not significantly different from that of gastric mucosal protectors ［RR=0.51(95%CI:0.18-1.41, P=0.19)］; the differences were statistically significant. Conclusion In short-term treatment with an LPRD course of no more than 4 weeks, PPIs significantly improved clinical efficacy compared with gastric mucosal protectors, but the incidence of adverse effects was not significantly different from that of gastric mucosal protectors.

Key words: Proton pump inhibitor, Gastric mucosal protective agents, Laryngopharygeal reflux disease, Meta-analysis

中图分类号:

R766.5

米雪芹,李松哲,邓英杰,李圣洋,肖丁齐,樊磊. 质子泵抑制剂与胃黏膜保护剂治疗咽喉反流性疾病临床疗效及安全性对比的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 136-142.

MI Xueqin, LI Songzhe, DENG Yingjie, LI Shengyang, XIAO Dingqi, FAN Lei. Meta-analysis of the clinical efficacy and safety of proton pump inhibitors versus gastric mucosal protective agents in the treatment of laryngopharyngeal reflux disease[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(6): 136-142.

参考文献

[1] 中华耳鼻咽喉头颈外科杂志编辑委员会咽喉组, 中华医学会耳鼻咽喉头颈外科学分会咽喉学组, 中华医学会耳鼻咽喉头颈外科学分会嗓音学组. 咽喉反流性疾病诊断与治疗专家共识(2022年,修订版)[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(10): 1149-1172. doi:10.3760/cma.j.cn115330-20220711-00428 Subspecialty Group of Laryngopharyngology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Laryngopharyngology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association; Subspecialty Group of Voice, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Experts consensus on diagnosis and treatment of laryngopharyngeal reflux disease(2022, revision)[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2022, 57(10): 1149-1172. doi:10.3760/cma.j.cn115330-20220711-00428
[2] 黄凤玲. 难治性LPRD与焦虑抑郁及自主神经功能的相关性研究[D]. 南宁: 广西医科大学, 2021
[3] 鲁明, 蔡继壹, 洪泽生, 等. 改变生活及饮食方式在咽喉反流性疾病治疗中的作用研究[J]. 中国耳鼻咽喉头颈外科, 2024, 31(4): 255-259. doi:10.16066/j.1672-7002.2024.04.011
[4] 梁志成,覃冠锻. 咽喉反流性疾病和负面情绪相关性研究进展 [J]. 中国医学文摘(耳鼻咽喉科学), 2024, 39(3): 118-121. doi:10.19617/j.issn1001-1307. 2024. 03. 118 LIANG Zhicheng,QIN Guanduan.Research advances in laryngopharyngeal reflux disease and negative mood associations[J].Chinese Medical Digest(Otorhinolaryngology), 2024, 39(3): 118-121. doi:10.19617/j.issn1001-1307. 2024. 03. 118
[5] 王颖, 周佳青. 慢性咽喉炎和反流性食管炎的相关性研究[J]. 中国耳鼻咽喉颅底外科杂志, 2011, 17(6): 476-480
[6] 崔玉兰, 周忠信. 质子泵抑制剂在反流性咽喉炎治疗中效果[J]. 中国医学文摘(耳鼻咽喉科学), 2021, 36(6): 128-129. doi:10.19617/j.issn1001-1307.2021.06.128 CUI Yulan, ZHOU Zhongxin. The effect of proton pump inhibitors in the treatment of reflux pharyngitis[J]. Chinese Medical Digest(Otorhinolaryngology), 2021, 36(6): 128-129. doi:10.19617/j.issn1001-1307.2021.06.128
[7] Gatta L, Vaira D, Sorrenti G, et al. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease[J]. Aliment Pharmacol Ther, 2007, 25(4): 385-392. doi:10.1111/j.1365-2036.2006.03213.x
[8] 张吉翔, 董卫国, 邱实, 等. 质子泵抑制剂治疗胃食管反流性咽喉炎的Meta分析[J]. 胃肠病学和肝病学杂志, 2012, 21(9): 834-840. doi:10.3969/j.issn.1006-5709.2012.09.016 ZHANG Jixiang, DONG Weiguo, QIU Shi, et al. The Meta-analysis for the effects of proton pump inhibitors on the treatment of gastroesophageal reflux laryngitis[J]. Chinese Journal of Gastroenterology and Hepatology, 2012, 21(9): 834-840. doi:10.3969/j.issn.1006-5709.2012.09.016
[9] 王焱, 刘英, 李芳, 等. 质子泵抑制剂的临床应用研究进展[J]. 中华保健医学杂志, 2021, 23(4): 415-416, 419. doi:10.3969/j.issn.1674-3245.2021.04.031
[10] 田鸣. 莫沙必利联合铝碳酸镁治疗胆汁反流性胃炎的疗效及安全性[J]. 黑龙江医药科学, 2018, 41(5): 68-69. doi:10.3969/j.issn.1008-0104.2018.05.031
[11] 毕冠芳. 质子泵抑制剂对反流性咽喉炎的治疗作用及安全性评价[J]. 糖尿病天地, 2023(7): 61-62. doi:10.3969/j.issn.1672-7851.2023.07.031
[12] 刘德刚. 质子泵抑制剂治疗反流性咽喉炎的临床疗效及其安全性[J]. 中国医学文摘(耳鼻咽喉科学), 2022, 37(1): 108-109, 136. doi:10.19617/j.issn1001-1307.2022.01.108 LIU Degang. Clinical efficacy and safety of proton pump inhibitors in the treatment of reflux laryngitis[J]. Chinese Medical Digest(Otorhinolaryngology), 2022, 37(1): 108-109, 136. doi:10.19617/j.issn1001-1307.2022.01.108
[13] 朱路路. 质子泵抑制剂治疗反流性咽喉炎的疗效及对患者症状的影响研究[J]. 科学养生, 2021, 24(9): 170. doi:10.3969/j.issn.1672-9714.2021.09.162
[14] 徐玉国. 质子泵抑制剂对反流性咽喉炎的治疗作用分析 [J]. 中国医学文摘(耳鼻咽喉科学), 2021, 36(1): 152-153,156.doi:10.19617/j.issn1001-1307. 2021. 01. 152 XU Yuguo. Therapeutic effect of proton pump inhibitors on reflux laryngitis[J]. Chinese Medical Digest(Otorhinolaryngology), 2021, 36(1): 152-153,156. doi:10.19617/j.issn1001-1307. 2021. 01. 152
[15] 王旭燕. 质子泵抑制剂应用于老年反流性咽喉炎治疗的效果研究[J]. 特别健康, 2018(13): 28-29. doi:10.3969/j.issn.2095-6851.2018.13.034
[16] 任玉莲. 泮托拉唑联合铝碳酸镁治疗反流性咽喉炎30例临床疗效研究[J]. 湖北科技学院学报(医学版), 2014, 28(4): 293-296 REN Yulian. Clinical efficacy research of treatment of pantoprazole with hydrotalcite for 30 patients with laryngopharyngeal reflux[J]. Journal of Hubei University of Science and Technology(Medical Sciences), 2014, 28(4): 293-296
[17] 张雅菲, 纪洋洋, 胡伟琦, 等. 康复新液联合埃索美拉唑治疗幽门螺杆菌阴性的反流性咽喉炎[J]. 中国眼耳鼻喉科杂志, 2019, 19(5): 328-331. doi:10.14166/j.issn.1671-2420.2019.05.010 ZHANG Yafei, JI Yangyang, HU Weiqi, et al. Curative effect of Kangfuxin combined with esomeprazole for Helicobacter pylori negative patients with laryngopharyngeal reflux disease[J]. Chinese Journal of Ophthalmology and Otorhinolaryngology, 2019, 19(5): 328-331. doi:10.14166/j.issn.1671-2420.2019.05.010
[18] 王荣国, 宋晓飞, 陈红耀, 等. 喉部上皮细胞形态、黏膜防御和炎症相关性基因在反流性咽喉炎患者的表达探究[J]. 中国耳鼻咽喉头颈外科, 2019, 26(9): 500-503. doi:10.16066/j.1672-7002.2019.09.009 WANG Rongguo, SONG Xiaofei, CHEN Hongyao, et al. Laryngeal epithelial cell morphology and expression of mucosal defense and inflammation-related genes in patients with reflux laryngitis[J]. Chinese Archives of Otolaryngology-Head and Neck Surgery, 2019, 26(9): 500-503. doi:10.16066/j.1672-7002.2019.09.009
[19] 陈旭东. 雷贝拉唑联合莫沙必利治疗胃食管反流性咽喉炎的效果评价[J]. 中国保健营养, 2021. 31(32): 190.
[20] 郭顺水. 雷贝拉唑与莫沙必利联用在胃食管反流性咽喉炎患者中的效果观察[J]. 北方药学, 2021, 18(8): 162, 166. doi:10.3969/j.issn.1672-8351.2021.08.074
[21] Lin RJ, Sridharan S, Smith LJ, et al. Weaning of proton pump inhibitors in patients with suspected laryngopharyngeal reflux disease[J]. Laryngoscope, 2018, 128(1): 133-137. doi:10.1002/lary.26696
[22] Lapeña JFF Jr, Ambrocio GMC, Carrillo RJD. Validity and reliability of the Filipino reflux symptom index[J]. J Voice, 2017, 31(3): 387. doi:10.1016/j.jvoice.2016.09.013
[23] Mössner J. The indications, applications, and risks of proton pump inhibitors[J]. Dtsch Arztebl Int, 2016, 113(27/28): 477-483. doi:10.3238/arztebl.2016.0477
[24] Yadlapati R, Kahrilas PJ. The “dangers” of chronic proton pump inhibitor use[J]. J Allergy Clin Immunol, 2018, 141(1): 79-81. doi:10.1016/j.jaci.2017.06.017

相关文章 15

[1]	胡志伟,陈冬,杨栋,吴继敏. 胃食管气道反流性疾病的诊断和治疗:基于2020~2024年相关共识和指南[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 30-38.
[2]	席晓宇,隋昕珂,陈升,李连勇,钟长青. 咽喉反流性疾病的内镜下治疗[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 61-65.
[3]	杜晨,闫燕,王丽,鹿培泉. 酸反流事件阈值设定对咽喉酸反流性疾病诊疗的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 115-119.
[4]	张斌,陈升,李冰,席晓宇,钟长青,高晓佩,李连勇,隋昕珂. 74例咽喉反流患者抗反流黏膜切除术后2年临床疗效分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 120-125.
[5]	周莹,王刚,王磊,张晓丽,韩浩伦,李保卫,孙喆喆,吴玮. 咽喉反流相关中耳炎1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 131-135.
[6]	王凯健,陈雪生,王威. 血小板-淋巴细胞比值与喉鳞状细胞癌预后相关性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 67-73.
[7]	李飏,刘鸫,曹文捷. 红光治疗对近视儿童等效球镜度、眼轴长度及脉络膜厚度影响的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 74-81.
[8]	张真,杨卓莹,周佳妮,张大为,陈仁杰. 环索奈德鼻喷剂治疗季节性过敏性鼻炎疗效与安全的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 13-20.
[9]	毕晓云,马本绪,王心茹,李旭豪,杨继国. 穴位贴敷治疗小儿过敏性鼻炎随机对照试验的Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(4): 75-85.
[10]	李泽鹏,李文建,孙志佳. 中成药治疗急性咽炎数据挖掘及网状Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(4): 111-118.
[11]	翟睿,李园,于敬龙,陈溪,郑酉友,刘兆兰,王俊宏. 揿针治疗变应性鼻炎临床疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 35-45.
[12]	张西,邓启成,张震,程瑶,王靖淞,赵锐,刘海. 营养支持对喉癌术后咽瘘影响的Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 51-59.
[13]	曾宪廷,王广科,孙占伟,武天义,李世超,王卫卫. 伴咽喉反流的难治性鼻窦炎术后应用质子泵抑制剂的疗效观察[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 189-194.
[14]	林曼青,周敏,陈腾宇,李丹,方彩珊,王睿智,朱锦祥,阮岩,徐慧贤,王培源. 中药鼻腔冲洗治疗慢性鼻窦炎术后有效性和安全性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 209-225.
[15]	姜雪莲, 张静月, 卫旭东. 基于Meta分析桥接网络药理学的鼻渊通窍颗粒治疗慢性鼻窦炎的疗效评价及潜在机制研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 226-236.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed